Clinical Trials Browser

OTHER × Salivary Gland Neoplasms × darolutamide × Clear all

NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Completed

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked